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ABSTRACT
Rationale Hospitalised patients with acute
exacerbation of COPD may deteriorate despite treatment,
with early readmission being common.
Objectives To investigate whether neural respiratory
drive, measured using second intercostal space parasternal
muscle electromyography (EMGpara), would identify
worsening dyspnoea and physician-deﬁned inpatient
clinical deterioration, and predict early readmission.
Methods Patients admitted to a single-site university
hospital with exacerbation of COPD were enrolled.
Spirometry, inspiratory capacity (IC), EMGpara, routine
physiological parameters, modiﬁed early warning score
(MEWS), modiﬁed Borg scale for dyspnoea and physician-
deﬁned episodes of deterioration were recorded daily until
discharge. Readmissions at 14 and 28 days post discharge
were recorded.
Measurements and main results 120 patients were
recruited (age 70±9 years, forced expiratory volume in 1 s
(FEV1) of 30.5±11.2%). Worsening dyspnoea, deﬁned as
at least one-point increase in Borg scale, was associated
with increases in EMGpara%max and MEWS, whereas an
increase in EMGpara%max alone was associated with
physician-deﬁned inpatient clinical deterioration.
Admission-to-discharge change (Δ) in the normalised value
of EMGpara (ΔEMGpara%max) was inversely correlated with
ΔFEV1 (r=−0.38, p<0.001) and ΔIC (r=−0.44, p<0.001).
ΔEMGpara%max predicted 14-day readmission (OR 1.13,
95% 1.03 to 1.23) in the whole cohort and 28-day
readmission in patients under 85 years (OR 1.09, 95% CI
1.01 to 1.18). Age (OR 1.08, 95% CI 1.03 to 1.14) and
12-month admission frequency (OR 1.29, 1.01 to 1.66),
also predicted 28-day readmission in the whole cohort.
Conclusions Measurement of neural respiratory drive by
EMGpara represents a novel physiological biomarker that
may be helpful in detecting inpatient clinical deterioration
and identifying the risk of early readmission among
patients with exacerbations of COPD.
Trial registration NCT01361451.
INTRODUCTION
Acute exacerbations of COPD (AECOPD) are
common, accounting for 12.5% of emergency
admissions in the UK1 with an in-hospital mortality
of up to 10%.2 Eighteen percent of patients with
AECOPD present to the emergency department
with acute hypercapnic respiratory failure3 and a
further 5% will develop late respiratory acidosis.
Twenty percent of hospitalised patients with
AECOPD are readmitted within 28 days,4 5 and
ﬁnancial penalties are now in operation for acute
care hospitals in the UK and USA for readmissions
within 30 days.6 7 It is a health economic priority
to identify COPD treatment failure promptly and
reduce readmissions, and biomarkers that can
achieve this will therefore be of signiﬁcant clinical
value.
Previous studies have reported the patient
characteristics that predict readmission among hos-
pitalised patients with COPD,2 8–11 but these are
limited by their dependence on non-modiﬁable
parameters, rather than on the trajectory of
response to treatment. In addition, early-warning
scores,12 often used to track inpatient clinical
deterioration and trigger escalation of care, vary in
their ability to predict outcomes such as critical
care admission and hospital mortality,13 limiting
the usefulness of these approaches.
More advanced physiological measurements of
elastic and threshold respiratory load are difﬁcult
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Key messages
What is the key question?
▸ Can non-invasive measurement of neural
respiratory drive identify clinical deterioration
and the risk of early readmission in patients
admitted with exacerbation of COPD?
What is the bottom line?
▸ Neural respiratory drive, measured by second
intercostal space parasternal muscle
electromyography, is a physiological biomarker
of worsening breathlessness and
physician-deﬁned clinical deterioration in COPD
exacerbations, and may predict early
readmission.
Why read on?
▸ The results of a large physiological
observational cohort study are presented,
validating a novel physiological biomarker that
represents the balance between the load and
the capacity of the respiratory muscle pump
during exacerbations of COPD.
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during an acute exacerbation as invasive monitoring of pleural
pressure is poorly tolerated. In addition, the measurement of
ventilation in ﬂow-limited patients characterised by neuroventi-
latory uncoupling, as a result of severe hyperinﬂation, has sig-
niﬁcant caveats and therefore the non-invasive measurement of
neural respiratory drive (NRD), which is a direct reﬂection of
the imbalance between respiratory muscle load and capacity,
would be a preferred option. Indeed, NRD as an advanced
physiological biomarker, provides a direct measure of the
balance between respiratory muscle load and capacity,14 and has
gained increasing attention in the acute setting.15
Recently, surface electromyography (EMG) of the second
intercostal space parasternal muscles (EMGpara) has been used as
a non-invasive alternative to the invasive oesophageal measure-
ment16 of NRD in patients with COPD, asthma and cystic ﬁbro-
sis.15 17 18 Murphy et al15 previously showed, in a pilot
feasibility study of this technique, that the change in NRD
during hospital admission was a biomarker of physician-deﬁned
clinical deterioration, and furthermore, change in NRD from
admission to discharge identiﬁed patients with COPD who were
readmitted within 14 days. However, this previous study was in
a small group of selected patients with COPD, with the majority
of patients having only a single pair of NRD measurements
made during their hospital admission.
We therefore hypothesised that, in a large, prospective obser-
vational cohort study of patients hospitalised with exacerbation
of COPD, changes in daily measurements of NRD between hos-
pital admission and discharge would predict readmission within
14 and 28 days. We further hypothesised that change in NRD
would objectively identify worsening dyspnoea and physician-
deﬁned clinical deterioration.
METHODS
Patients
The study was approved by the London-Bentham Research
Ethics Committee and participants provided written informed
consent. The authors registered the study as an observational
cohort study (NCT01361451). Patients with a physician diagno-
sis of acute exacerbation of COPD, deﬁned according to clinical
features and basic investigations,1 were enrolled within 12 h of
admission to a UK teaching hospital. The requirement for
admission was determined by the attending physician. Patients
were excluded if they had another cause for their acute
admission (eg, acute heart failure, PE), cognitive impairment,
active cancer or signiﬁcant psychosocial factors.
Admission data
Demographic and anthropometric data were collected. FEV1,
FVC and inspiratory capacity (IC)19 were measured using a
pneumotachometer (3830, Hans-Rudolph, Shawnee, USA) or a
handheld spirometer (Micro, Carefusion, Basingstoke, UK)
according to international standards.20 Symptoms were assessed
using the Medical Research Council (MRC) Dyspnoea scale,21
the modiﬁed Borg scale for dyspnoea22 and the COPD
Assessment Test (CAT).23 Standard physiological observations
(respiratory rate, heart rate, oxygen saturation, body tempera-
ture and blood pressure) were collected; an aggregate score
derived from these was recorded as the modiﬁed early warning
score (MEWS), according to local protocol.
EMGpara measurement
EMGpara was measured with patients in a semi-recumbent or
seated position, as previously described.15 After skin prepar-
ation, two surface electrodes (Blue Sensor Q, Ambu, St Ives,
UK) were placed in the second intercostal spaces, immediately
lateral to the sternum. The skin was marked to allow placement
of electrodes in an identical position throughout the study.
Nasal cannulae connected to a differential pressure transducer
(Technical services, Lane Fox Respiratory Unit, London, UK)
identiﬁed inspiration and expiration phases (ﬁgure 1). EMGpara
signals were ampliﬁed and sampled at 2 kHz (Dual Bioamp and
Powerlab, AD Instruments, Chalgrove, UK). Signals were ana-
lysed using Labchart software (AD Instruments) on a personal
computer. The peak root mean square EMGpara activity for each
inspiration was averaged over 1 min of tidal breathing and nor-
malised to a value of EMGpara obtained during a maximal
inspiratory sniff manoeuvre, obtained before each measure-
ment.15 Two measures of NRD were derived, including (1)
EMGpara%max, the mean peak inspiratory tidal EMGpara normal-
ised to the maximal manoeuvre; and (2) NRDI (Neural
Respiratory Drive Index), the product of EMGpara%max and
respiratory rate.15
Study protocol
EMGpara, modiﬁed Borg scale, FEV1, FVC and IC were mea-
sured at least daily, between admission and medical ﬁtness for
Figure 1 Representative trace of
nasal pressure and second intercostal
space parasternal electromyogram
during tidal breathing in a patient with
COPD during an exacerbation. Pnp,
nasal pressure; EMGpara, parasternal
electromyogram; RMSpara, root mean
square of EMGpara.
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discharge, and at least 2 h after the last bronchodilator dose.
Medical ﬁtness for discharge was determined by the senior
attending physician, which was either senior resident or consult-
ant. Supplemental oxygen was provided as instructed by the
attending physicians. Patients were settled at rest for 7 min
before EMGpara traces were acquired for analysis. Patients
requiring non-invasive ventilation (NIV) had measurements
taken after 10 min off NIV. The attending physicians, who were
blinded to EMGpara data, were asked to provide an opinion
regarding clinical improvement or deterioration between succes-
sive assessments. EMGpara data were analysed after patients’ dis-
charge from hospital. Data for readmissions and deaths were
obtained from patients and their relatives, and from medical
records. Admission-to-discharge changes in EMGpara%max and
NRDI were expressed as ΔEMGpara%max and ΔNRDI, respect-
ively. Changes in EMGpara%max and NRDI between consecutive
inpatient measurements were denoted ΔEMGpara%max,cons and
ΔNRDIcons, respectively.
Primary endpoint and power calculation
Although this was an observational cohort study, an a priori
primary endpoint of 28-day readmission was taken as this was
considered to have major clinical relevance to the current ﬁnan-
cial penalty systems for readmission in the UK and USA.
Secondary endpoints were 14-day readmission and clinical
deterioration, deﬁned by (1) at least one-point increase in Borg
scale24 between consecutive recordings, or (2) attending phys-
ician opinion. A sample size of 120 was determined from pub-
lished pilot data15 with a presumed 28-day readmission rate of
20% to detect a difference in NRDI of 203/min between
readmitted and non-readmitted patients with a power of 80%.
Statistical analysis
Paired data were analysed using t or Wilcoxon signed-rank
tests. Readmitted and non-readmitted groups were compared
using independent t or Mann–Witney U tests. Death after dis-
charge without early readmission was analysed together with
readmissions. Logistic regression and receiver-operator charac-
teristic (ROC) analyses were used to identify, and test the
utility of, predictors of readmission. Kaplan–Meier plots and
log rank tests were used to analyse time to readmission.
Generalised linear mixed model (GLMM) analyses were used
to assess the association between ΔEMGpara%max,cons and epi-
sodes of worsening dyspnoea or with physician-deﬁned deteri-
oration. For the purposes of this study, death was analysed with
the readmission data.
RESULTS
Admission, clinical course and readmission data
A total of 131 patients were enrolled between January 2011
and September 2013 (see online supplementary ﬁgure E1),
and 120 patients completed the study between admission and
discharge (table 1). Twenty (16.7%) patients were unable to
perform FEV1 and FVC manoeuvres at admission, while 27
(22.5%) patients could not perform admission IC manoeuvres.
Three (2.5%) patients declined arterial blood gas sampling.
Eight (6.7%) patients required NIV or high-dependency care
following admission to hospital. There were no patients who
received high-ﬂow humidiﬁed oxygen therapy. A further three
(2.5%) patients deteriorated more than 12 h after admission
and required NIV. Median length of hospital stay was 3 (IQR
2–6) days. Median interval from the date of medical ﬁtness
for discharge to the date of discharge was 0 (IQR 0–1) days.
One patient died 3 days after discharge from hospital.
Fourteen-day and 28-day readmission rates were 12.5% and
21.7%, respectively. The single death was analysed with the
readmission data.
Early warning scores, symptom scores and physiological data
MEWS, modiﬁed Borg scale and CAT scores all improved from
admission to discharge (table 2). FEV1, FVC and IC increased
over this period, with a concomitant fall in EMGpara%max and
NRDI (table 2).
Table 1 Baseline characteristics at admission to hospital
Anthropometrics, smoking and previous exacerbations
Age (years) 70 (9)
Male (%) 58 (48.3)
BMI (kg/m2) 25.3 (7.2)
Current smokers (%) 47 (39.2)
Smoking history (pack years) 40 (25–50)
Exacerbation frequency (/12 months) 3 (1–5)
Hospital admission frequency (/12 months) 1 (0–2)
Current exacerbation history
Duration of symptoms (days) 4 (2–7)
Systemic steroids prior to admission (%) 26 (21.7)
Antibiotics prior to admission (%) 30 (25.0)
Comorbidities
Ischaemic heart disease (%) 34 (28.3)
Cerebrovascular disease (%) 13 (10.8)
Hypertension (%) 53 (44.2)
Diabetes mellitus (%) 20 (16.7)
Disease severity
GOLD stage 2 (%)* 4 (4)
GOLD stage 3 (%)* 36 (36)
GOLD stage 4 (%)* 60 (60)
MRC dyspnoea grade 4 (4–5)
Admission investigations
Arterial blood gases†
pH 7.39 (0.06)
paCO2 (kPa) 5.82 (1.39)
paO2 (kPa) 8.83 (2.98)
Bicarbonate (mEq/L) 25.7 (3.8)
Base excess (mmol/L) 0.63 (3.1)
Lactate (mmol/L) 1.7 (1.5)
Routine laboratory tests
C-reactive protein (mmol/L) 65 (100)
Creatinine (μmol/L) 72 (45)
Fibrinogen (mmol/L)‡ 4.6 (1.5)
Leucocytes (×103/mL) 11.9 (4.8)
Neutrophils (×103/mL) 8.4 (5.0)
Eosinophils (×103/mL) 0.3 (0.7)
Haemoglobin (g/dL) 13.8 (1.7)
Platelets (×109/L) 259 (87)
Radiographic consolidation 25 (20.8)
Length of hospital stay (days) 3 (2–6)
Deaths within 28 days (%) 1 (0.8)
Readmission within 28 days (%) 26 (21.7)
Deaths within 14 days (%) 1 (0.8)
Readmission within 14 days (%) 15 (12.5)
Mean (SD), Median (IQR) or N (%).
*N=100.
†N=117.
‡N=68.
BMI, body mass index; GOLD, Global initiative for chronic Obstructive Lung Disease;
MRC, Medical Research Council; PaCO2, arterial partial pressure of carbon dioxide;
PaO2, arterial partial pressure of oxygen.
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Relationship between NRD, physiological parameters
and dyspnoea
Admission-to-discharge change (Δ) in EMGpara%max was
inversely correlated with ΔFEV1 (r=−0.38, p<0.001), ΔFVC
(r=−0.31, p=0.003) and ΔIC (r=−0.44, p<0.001) (ﬁgure 2).
However, there was no correlation between ΔEMGpara%max and
Δmodiﬁed Borg scale, ΔCAT score or ΔMEWS. Increases in
FEV1 and IC were independently associated with reductions in
EMGpara%max on multiple linear regression analysis (ΔFEV1
standardised coefﬁcient β=−0.36, p=0.001; ΔIC β=−0.26,
p=0.019). ΔEMGpara%max was weakly correlated with age
(r=+0.24, p=0.009). ΔNRDI was weakly inversely correlated
with ΔFEV1 (r=−0.30, p=0.004), ΔFVC (r=−0.29, p=0.007)
and ΔIC (r=−0.40, p<0.001), as well as with body mass index
(r=−0.27, p=0.005). There were no correlations between
ΔNRDI and ΔBorg scale or ΔMEWS.
Predictors of readmission within 28 days
Twenty-seven (22.5%) patients were readmitted or died within
28 days of hospital discharge. Independent sample analysis
showed signiﬁcant differences in age, MRC grade, admission
haemoglobin levels, hospital admission frequency in the previ-
ous 12 months (admission frequency), ΔEMGpara%max and
ΔNRDI between readmitted and non-readmitted groups at
28 days (table 3). There were no signiﬁcant differences in the
values of EMGpara%max and NRDI at discharge between the two
groups. With the exception of the MRC grade, univariate ana-
lysis demonstrated that all of these parameters predicted
readmission at 28 days (table 4). However, in multivariable step-
wise logistic regression analysis, only age and admission fre-
quency predicted 28-day readmission (adjusted OR 1.08, 95%
CI 1.03 to 1.14, p=0.004, and adjusted OR 1.29, 95% CI 1.01
to 1.66; p=0.043, respectively). Change in EMGpara%max
between admission and discharge did not predict 28-day
readmission in the whole cohort. The rate of radiographic
consolidation was not signiﬁcantly different between the two
groups (11.1% for the readmitted vs 23.7% for the non-
readmitted group; p=0.16).
In accordance with the correlation, albeit weak, between
ΔEMGpara%max and age, a post hoc, exploratory analysis was
performed among patients below an arbitrary age cut-off of
85 years (n=112). There were 23 (20.5%) readmissions within
28 days among these patients. Under these circumstances, older
age (adjusted OR 1.10, 95% CI 1.02 to 1.16; p=0.017) and
increasing EMGpara%max between admission and discharge
(adjusted OR 1.09, 95% CI 1.01 to 1.18, p=0.023) were pre-
dictive of 28-day readmission. ROC analysis for the prediction
of 28-day readmission in patients under 85 years produced an
area under the ROC curve (AUC) of 0.70 for age and 0.66 for
ΔEMGpara%max.
Predictors of readmission within 14 days
Sixteen (13.3%) patients were readmitted or died within
14 days of discharge. There were differences in MRC grade and
Figure 2 Relationship between admission-to-discharge change
in EMGpara%max, and changes in (A) FEV1, (B) FVC and (C) IC.
EMGpara%max, 1 min mean magnitude of rectiﬁed inspiratory
parasternal EMG activity normalised to a maximal manoeuvre;
IC, inspiratory capacity.
Table 2 Physiological measurements at admission and discharge
Admission Discharge p Value
Spirometry
FEV1 (L)* 0.69 (0.28) 0.75 (0.31) <0.001
FVC (L)* 1.51 (0.56) 1.63 (0.54) 0.02
FEV1%predicted (%)* 30.5 (11.2) 33.7 (12.2) <0.001
FEV1/FVC ratio (%)* 47.4 (12.8) 48.9 (13.2) 0.184
Inspiratory capacity (L)† 1.39 (0.58) 1.56 (0.63) <0.001
Symptom scores
Modified Borg scale 3 (2–5) 2 (1–3) <0.001
COPD assessment test 29 (24–32.75) 24 (17–29) <0.001
Routine observations
SpO2 (%) 92.6 (3.5) 93.4 (2.8) 0.024
Temperature (°C) 36.5 (0.6) 36.3 (0.5) 0.023
Heart rate (/min) 97.2 (15.8) 84.8 (12.9) <0.001
Respiratory rate (/min) 23.1 (4.3) 20.4 (2.4) 0.024
MEWS 3 (2–5) 2 (1–3) <0.001
Parasternal EMG parameters
Sniff (maximum) EMG (μV) 74.8 (37.3) 76.5 (39.1) 0.35
EMGpara%max (%) 17.4 (8.2) 15.8 (7.3) 0.017
NRDI (/min) 372 (205) 329 (196) 0.018
Values are expressed as mean (SD) or median (IQR).
*N=100.
†N=93.
EMG, electromyography; MEWS, medical early warning score; NRDI, Neural
Respiratory Drive Index; SpO2, transcutaneous oxygen saturation.
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ΔEMGpara%max between the readmitted and non-readmitted
groups (table 5), but MRC grade did not predict 14-day
readmission in the univariate logistic regression model (table 6).
Only admission-to-discharge increases in EMGpara%max (adjusted
OR 1.12, 95% CI 1.03 to 1.21, p=0.005) predicted 14-day
readmission on multivariable stepwise logistic regression ana-
lysis. ROC analysis for the prediction of 14-day readmission
gave an AUC of 0.70 for ΔEMGpara%max. By contrast, AUC for
ΔFEV1 and ΔIC were 0.57 and 0.56, respectively (ﬁgure 3). The
failure of ΔEMGpara%max to fall by more than 3.1% between
admission and discharge had a sensitivity of 93.8% and a speci-
ﬁcity of 41.3% to detect 14-day readmission, with a positive
predictive value (PPV) of 19.7% and a negative predictive value
(NPV) of 97.7%. Again, there was a non-signiﬁcant difference
in the rate of radiographic consolidation between the groups
(6.25% for the readmitted vs 23.1% for the non-readmitted
group, p=0.123). Kaplan–Meier analysis showed that patients
whose EMGpara%max failed to fall by less than 3.1% between
admission and discharge had a shorter time to readmission than
those whose EMGpara%max fell by more than 3.1% (log rank test
p=0.03) (ﬁgure 4).
When ΔNRDI was used instead of ΔEMGpara%max in the
regression model as a measure of NRD, it also predicted 14-day
readmission or death (ΔNRDI: OR 1.003, 95% CI 1.001 to
1.006, p=0.01). ROC analysis for the prediction of 14-day
readmission gave an AUC of 0.70 for NRDI.
Detection of in-hospital clinical deterioration
A total of 475 pairs of consecutive EMGpara data were acquired
from the 122 patients who provided at least one pair of analys-
able data; although 120 patients completed investigations
between hospital admission and discharge, two further patients
gave at least one pair of analysable data before withdrawal from
the study. Patients had a median of three pairs of measurements
(range 1–23) between admission and discharge. There were 116
episodes of worsening dyspnoea, deﬁned as at least one-point
increase in Borg scale. On univariate GLMM analysis, an
increase in MEWS (ΔMEWScons) and in EMGpara%max
(ΔEMGpara%max,cons) between consecutive recordings was asso-
ciated with symptomatic deterioration (table 7). Multivariable
GLMM analysis showed that ΔMEWScons (adjusted OR 1.36,
95% CI 1.01 to 1.84, p=0.04) and ΔEMGpara%max,cons (adjusted
OR 1.07, 95% CI 1.01 to 1.14, p=0.027) were independently
associated with worsening of dyspnoea. Multivariable GLMM
analysis showed that ΔEMGpara%max,cons (coefﬁcient 0.05, 95%
CI 0.01 to 0.09, p=0.024) and ΔICcons (coefﬁcient −1.11, 95%
CI −2.19 to −0.03, p=0.044) were independently associated
with changes in Borg scale of any magnitude between consecu-
tive recordings.
There were 35 episodes of physician-deﬁned deterioration.
Only an increase in EMGpara%max between consecutive measure-
ments was associated with physician-deﬁned deterioration
(ΔEMGpara%max,cons OR 1.030, 95% CI 1.003 to 1.055,
p=0.03).
Table 3 Differences between readmitted and non-readmitted
patients within 28 days
28-day readmission
Non-readmitted
at 28 days
N=27 N=93 p Value
Age (years) 75 (9) 68 (9) 0.001
MRC dyspnoea grade 5 (4–5) 4 (3–5) 0.013
Admission frequency
(/12 months)
1 (1–3) 0 (0–2) 0.006
Admission haemoglobin
(g/dL)
13.1 (1.8) 14.0 (1.7) 0.017
ΔEMGpara%max (%) +1.5 (8.4) −2.4 (7.2) 0.018
ΔNRDI (/min) +28 (217) −64 (189) 0.032
ΔModified Borg scale −2 (−2.5 to −2) −1 (−3 to −1) 0.58
ΔCAT −7 (−12 to 0) −5 (−9 to 0) 0.30
ΔRespiratory rate (/min) −3.2 (5.3) −2.6 (4.0) 0.50
Values are expressed as mean (SD) or median (IQR).
CAT, COPD Assessment Test; EMGpara%max, 1 min mean magnitude of rectified
inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC,
Medical Research Council; NRDI, Neural Respiratory Drive Index.
Table 4 Univariate logistic regression analysis for predictors of
28-day readmission
OR p Value 95% CI
Age 1.09 0.002 1.03 to 1.15
Hospital admission frequency 1.35 0.013 1.07 to 1.71
Haemoglobin 0.73 0.020 0.56 to 0.95
ΔEMGpara%max 1.08 0.022 1.01 to 1.15
ΔNRDI 1.002 0.036 1.000 to 1.005
ΔModified Borg scale 1.07 0.49 0.88 to 1.29
ΔCAT 0.98 0.82 0.93 to 1.03
ΔRespiratory rate 0.97 0.50 0.88 to 1.07
CAT, COPD Assessment Test; EMGpara%max, 1 min mean magnitude of rectified
inspiratory parasternal EMG activity normalised to a maximal manoeuvre; NRDI,
neural respiratory drive index.
Table 5 Differences between readmitted and non-survivors and
non-readmitted survivors within 14 days
14-day readmission
or death
Non-readmitted
at 14 days
p ValueN=16 N=104
MRC dyspnoea grade 5 (4–5) 4 (4–5) 0.039
ΔEMGpara%max (%) +3.6 (8.3) −2.3 (7.2) 0.003
ΔNRDI (/min) +71 (221) −61 (190) 0.012
ΔModified Borg scale −0.25 (−2 to 1) −1 (−3 to 0) 0.12
ΔCAT −8.5 (−11 to −2) −5 (−9 to 1) 0.16
ΔRespiratory rate (/min) −2.6 (3.5) −2.8 (4.4) 0.87
Values are expressed as mean (SD) or median (IQR).
CAT, COPD Assessment Test; EMGpara%max, 1 min mean magnitude of rectified
inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC,
Medical Research Council; NRDI, Neural Respiratory Drive Index.
Table 6 Univariate logistic regression analysis for predictors of
14-day readmission
OR p Value 95% CI
MRC dyspnoea grade 1.86 0.09 0.92 to 3.76
ΔEMGpara%max 1.12 0.005 1.03 to 1.21
ΔNRDI 1.003 0.014 1.001 to 1.006
ΔModified Borg scale 1.23 0.10 0.96 to 1.57
ΔCAT 0.99 0.67 0.92 to 1.05
ΔRespiratory rate (/min) 1.01 0.87 0.89 to 1.15
Values are expressed as mean (SD) or median (IQR).
CAT, COPD Assessment Test; EMGpara%max, 1 min mean magnitude of rectified
inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC,
Medical Research Council; NRDI, Neural Respiratory Drive Index.
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DISCUSSION
In this single-centre validation study of an advanced physio-
logical biomarker performed in an unselected cohort of acutely
unwell patients with COPD, the failure of NRD to fall between
admission and discharge predicted readmission within 14 days
of discharge. Furthermore, this failure was predictive of
readmission within 28 days in those patients under 85 years of
age, but not in the cohort as a whole. In addition to the utility
of this test to predict clinical outcome following hospital dis-
charge, an increase in NRD between consecutive daily measure-
ments detected episodes of worsening dyspnoea and
physician-deﬁned in-hospital clinical deterioration. The physio-
logical rationale of employing NRD was strongly supported by
the relationship with change in respiratory muscle physiological
load between admission and discharge.
Critique of the method
Every attempt was made to enrol consecutive eligible patients
with a screening to recruitment ratio of 3.4:1 achieved, which is
acceptable for such an observational detailed physiological
study. Few of the patients enrolled into this study required non-
invasive or invasive ventilation at admission, which adds to the
generalisability of this study and indeed the current cohort was
wholly representative of UK patients admitted to the acute
medical wards.2 Patients presenting in acute hypercapnic respira-
tory failure were frequently unable to provide written informed
consent, and the study did not have ethical approval for proxy
assent and retrospective patient consent.
In line with our previous work,15 up to one-ﬁfth of patients
were unable to perform forced respiratory manoeuvres at admis-
sion, which supports the clinical rationale for non-invasive mea-
surements, such as EMGpara, being performed during resting
tidal breathing. This could be accommodated into the routine
monitoring of acutely unwell patients with COPD as a measure
of the respiratory load–capacity balance. The acquisition of
respiratory EMG needs to be performed in a standardised
manner as variations in electrode position and skin preparation
can have a small inﬂuence on the magnitude of the signals;
however, we have previously published data demonstrating the
reproducibility of EMGpara.
15 18 Although there was variability
in the value of the maximal EMG obtained during the sniff pro-
cedure between admission and discharge (see online supplemen-
tary ﬁgure E2), there was no overall increase during the course
of the hospital stay and therefore it is unlikely that the reduction
in EMGpara%max between admission and discharge was driven
by a fall in the maximal EMGpara.
Figure 3 Receiver-operator curves for prediction of 14-day readmission for (A) ΔEMGpara%max, (B) ΔFEV1, and (C) ΔIC. EMGpara%max, 1 min mean
magnitude of rectiﬁed inspiratory parasternal EMG activity normalised to a maximal manoeuvre; IC, inspiratory capacity; ROC, receiver-operator
curve; AUC, area under the receiver-operator curve.
Figure 4 Time-to-readmission Kaplan–Meier plots for patients whose
EMGpara%max fell by more than 3.1% between admission and discharge
(solid line), and those whose EMGpara%max fell by less than 3.1%
(dotted line). EMGpara%max, 1 min mean magnitude of rectiﬁed
inspiratory parasternal EMG activity normalised to a maximal
manoeuvre.
Table 7 Generalised linear mixed modelling analysis for factors
associated with clinical deterioration in symptoms as defined by ≥1
point increase in Borg scale
Adjusted OR p Value 95% CI
ΔMEWScons 1.157 0.048 1.001 to 1.338
ΔEMGpara%max,cons (%) 1.05 0.001 1.02 to 1.08
ΔEMGpara%max,cons, change in EMGpara%max between consecutive inpatient
measurements; EMGpara%max, 1- min mean magnitude of rectified inspiratory
parasternal EMG activity normalised to a maximal manoeuvre; ΔMEWScons, change
in modified early warning score between consecutive measurements.
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Clinical applicability of the ﬁndings
Readmission within 14 days
Although the cut-off level for ΔEMGpara%max of −3.1% has a
low PPV for 14-day readmission, the high NPV indicates that
NRD has clinical utility as a risk-stratiﬁcation tool for patients
with COPD being discharged from hospital. Patients whose
EMGpara%max falls by more than 3.1% during hospital admis-
sion are at very low risk of 14-day readmission and indeed these
patients have greater time to readmission. The selected cut-off
value is similar in magnitude to the fall in EMGpara%max
observed amongst non-readmitted patients in the pilot study of
Murphy et al,15 indicating the reproducibility of this technique.
Pharmacological and technological therapies could be used in
future studies to target a reduction in EMGpara, with the aim of
optimising pulmonary mechanics, which could potentially
reduce readmission rates. The cut-off value of −3.1% requires
further prospective validation to become a useful clinical tool.
Readmission within 28 days
The admission-to-discharge change in NRD failed to predict
28-day readmission across all age groups. This is perhaps unsur-
prising as several previous studies have shown that age25 26 and
admission frequency8 27 are strongly predictive of readmission.
In elderly patients, functional impairment and the burden of
chronic disease28 play a major role in inﬂuencing readmission
and, in the current study, it appears to be more inﬂuential than
the failure to enhance the respiratory muscle load–capacity
balance. The current data support the concept that the inpatient
trajectory of NRD was a key factor inﬂuencing 14-day readmis-
sion in all age groups and 28-day readmission in those patients
less than 85 years of age. Early readmission, under these circum-
stances, indicates a failure of the inpatient treatment to modify
the airways obstruction and lung hyperinﬂation, and thereby to
ameliorate the respiratory muscle load–capacity balance. Future
studies should focus on strategies to modify the load–capacity
balance and reduce NRD with the aim of promoting safe dis-
charge. The authors acknowledge the limitations of the post-hoc
application of an age cut-off of 85 years and wholly appreciate
that this is an exploratory analysis and prospective validation
will be required to assess 28-day readmission. However, this
does not detract from the potential clinical implications of this
approach and this analysis ensures that the appropriate target
patient group are recruited into any future trials.
Clinical deterioration during admission
We have shown that increases in EMGpara predicted worsening
of dyspnoea during hospital admission. NRD has the potential
to be used to deliver enhanced monitoring for patients who are
either unable to communicate their clinical condition effectively
or those who fail to recognise the severity of their symptoms,
which is a priority in healthcare systems where clinical
resources, in terms of nursing and other clinical personnel, are
increasingly being rationed. Although Murphy et al15 found
that EMGpara distinguished between physician-deﬁned improve-
ment and deterioration, this was only in a small number of epi-
sodes. We have reproduced these ﬁndings in a much larger
unselected cohort. Importantly, ΔEMGpara%max was the only
parameter that correlated with physician-deﬁned deterioration,
supporting NRD as a physiological biomarker for the early
identiﬁcation of treatment failure.
Physiological validity of NRD in the acute setting
In this cohort of acutely unwell patients with COPD, we
observed a correlation between ΔEMGpara%max and ΔFEV1,
supporting the hypothesis that EMGpara reﬂects the resistive
load imposed on the respiratory system during an acute exacer-
bation. Furthermore, there was a direct relationship between
ΔEMGpara%max and ΔIC, indicating that changes in the elastic
and threshold loads imposed by hyperinﬂation can be detected
by EMGpara. It appears therefore, that EMGpara reﬂects the
changes in pulmonary mechanics that accompany an exacerba-
tion of COPD. While the reduction in NRD with decreasing
hyperinﬂation may be due, in part, to the increase in respiratory
muscle length, rather than due to a reduction in NRD,29 animal
studies of parasternal intercostal muscle activation at high lung
volume have shown that parasternal muscle EMG tends to
remain stable despite acute lung hyperinﬂation.
CONCLUSION
During recovery from an acute exacerbation of COPD requiring
hospital admission, change in NRD from admission to discharge
predicted 14-day readmission in all age groups and 28-day hos-
pital readmission in patients under 85 years old. In addition,
change in NRD between successive inpatient measurements was
able to detect worsening dyspnoea and physician-deﬁned clinical
deterioration. Second intercostal space parasternal EMG is a
novel advanced physiological monitoring tool that may be clin-
ically useful in identifying treatment failure during hospital
admission and for predicting safe discharge, which is a priority
for all acute healthcare organisations.
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